| ALLIANCE |
In the second agreement, Serono will collaborate with the Swiss company NovImmune to develop two of NovImmune's fully human monoclonal antibodies, NI-0401 and NI-0501. One antibody targets the CD3 antigen, a regulator in the activation of T cells, a hallmark of many autoimmune diseases. The other targets interferon-ã, a cytokine involved in the regulation of immune and inflammatory responses. The two materials are currently in preclinical development. NovImmune will be responsible for the two products until the completion of Phase IIa clinical trials, when Serono will take over development. Serono will make a $6.1 million equity investment in NovImmune and could make milestone payments of up to $105 million, as well as pay royalties. |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |